|
|
|
|
|
|
|
|
| February 18, 2008 | Alligator Bioscience and ImmuRx enter into strategic collaboration
| | Lund, February 12, 2008 - Alligator Bioscience and ImmuRx today announced that they have entered into a strategic collaboration. Alligator and ImmuRx will use their proprietary technology platforms to develop a cancer vaccine adjuvant.
About Alligator Bioscience AB
Alligator Bioscience discovers and develops early protein drug candidates. The method used is the company’ own patented FIND® technology (Fragment Induced Diversity). Established in 2001 in Lund, Sweden, the company currently has 23 employees. Alligator Bioscience has successfully collaborated with several companies in the pharmaceutical, diagnostic and biotech industry and created an internal pipeline of therapeutic drug candidates. The areas of indication on which Alligator is focused are inflammatory diseases and cancer.Alligator Bioscience operates from the Ideon Science Park in Lund, Sweden.For further general information please visit www.alligatorbioscience.com.
About ImmuRx
Inc.ImmuRx Inc. is a biopharmaceutical company developing an adjuvant platform that stimulates the immune system to fight a wide variety of cancers and chronic infections. ImmuRx has developed the leading intellectual property estate for combinations of stimulants that trigger both the innate and adaptive halves of the immune system, producing more powerful and safer treatments. ImmuRx is based in Lebanon, New Hampshire, USA.For further general information please visit www.ImmuRx.com.
If you have any questions please contact
Dr Gun-Britt Fransson,
CEO of Alligator Bioscience AB,
+46 46 286 4284
or
David DeLucia,
CEO of ImmuRx,
+1 802-649-8109.
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| June 14, 2010 |
Alligator Bioscience AB appoints Sibylle Lenz as Chief Executive Officer
Read more >>
| |  |
| 15 april 2010 | Del 2 av riktad emission tillför Alligator Bioscience AB drygt 5 MSEK
Denna andra del av den riktade emissionen tillför Alligator Bioscience AB 5.025.000 SEK (av de 5,6 miljoner SEK som återstod av bemyndigandet som gavs vid årsstämman 2009. Emissionskursen, 15 kr per aktie, var samma som vid första delen av emissionen som genomfördes under 2009.
Antalet aktier som tillförs är 335.000. Totala antalet aktier efter emissionen är 15.285.820.
| | |
| 12 april 2010 | |
| | |
| 8 februari 2010 | Alternativa Aktiemarknaden har trots påtryckningar från Alligator Bioscience beslutat att ännu inte upphöra med noteringen på Alternativas handelsplats för onoterade aktier. Alligator vill därför åter klargöra att beslutet att inleda handel med Alligator Biosciences aktier skett utan någon som helst medverkan från bolagets sida. Alligator har uppmärksammat Finansinspektionen på den uppkomna situationen.
| | |
| 20 januari 2010 |
Alternativa aktiemarknadens initiativ
Alternativa aktiemarknaden har i januari 2010 beslutat inleda handel med Alligator Bioscience ABs aktier. Detta har skett utan Alligators medverkan och i strid med bolagets vilja. Alligator har bett Alternativa aktiemarknaden att upphöra med noteringen av bolagets aktier
| | |
| Januari 11, 2010 | Alligator Bioscience´s protein drug candidate ADC-1004 for treatment of ischemia reperfusion (I/R) injury reduced myocardial infarct size in a porcine model
| | Read more>>
| |
| December 2, 2009 | | Alligator Bioscience Awarded New Patent for its Protein Optimization Technology FIND® in Japan
| | Read more>>
| |
| 1 december 2009 | Per-Olof Mårtensson lämnar styrelsen
Per-Olof Mårtensson har, efter en lång och framgångsrik karriär inom internationell läkemedels, bioteknik och medicinsk teknisk industri, under de senaste åren valt att stegvis trappa ner sina engagemang och har nu beslutat sig för att lämna styrelsen för Alligator Bioscience AB.
| | Read more >>
| |
| 9 november 2009 | Vår företrädesemission är nu avslutad
Denna, tillsammans med den riktade emission vi hade tidigare under året, tillförde bolaget 41,5 miljoner kronor. Kursen var 15 kronor i båda emissionerna.
| | |
| 10 oktober 2009 | Samarbetsavtal med ett amerikanskt bioteknikbolag
Alligator Bioscience AB har tecknat ett samarbetsavtal med ett amerikanskt bioteknikbolag som utvecklar proteinläkemedel
| | Read More >>
| |
| 22 september 2009 | Redeye Company Report
Alligator Bioscience: Utvecklar nästa generations bioläkemedel
| | Read more >>
| |
| September 17, 2009 | | Alligator Bioscience enters into research and option agreement with BioInvent to jointly develop Antibody-based therapeutics for novel treatments for oncology indications
| | Read more>>
| |
| April 30, 2009 | | Biotecnol successfully completes milestone of process development and manufacturing activities for Alligator Bioscience AB inflammation programme ADC -1004
| Read more>>
| |
November 25, 2008
| Alligator Bioscience AB, the protein optimization company, to Present at the Rodman & Renshaw 10th Annual Healthcare Conference.
| | Read more >>
| |
| June 16, 2008 | Alligator Bioscience AB and PolyTherics Ltd announce strategic collaboration for optimisation of next generation biopharmaceuticals
| | Read more >>
| |
| February 18, 2008 | Alligator Bioscience and ImmuRx enter into strategic collaboration
| | Read more>>
| |
| November 9, 2007 | Alligator Bioscience strengthens its FIND® patent portfolio
| | Read more>>
| |
| September 17, 2007 | Alligator Bioscience and SARomics have entered into a collaboration agreement
| | Read more>>
| |
| September 11, 2007 | | Alligator Bioscience strengthens its FIND® patent portfolio
| | Read more>>
| |
| June 11, 2007 | Alligator Bioscience raises an additional 10,7 MSEK in second closing
| | Read more>>
| |
| May 29, 2007 | | Alligator Bioscience raises 51 MSEK in new share issue
| | Read more>>
| |
| April 20, 2007 | | Alligator Bioscience AB launches FINDbind™, an efficient method for affinity maturation of antibodies
| | Raed more>>
| |
| December 15, 2006 | | Alligator Bioscience AB has received a grant from Vinnova for further evaluations of the FIND® technology platform
| | Raed more>>
| |
| December 1, 2006 | | Alligator Bioscience AB and Axis-Shield ASA moves successful project into next phase
| | Read more>>
| |
| October 26, 2006 | | Alligator Bioscience AB has reached a successful milestone in its collaboration with Bayer HealthCare AG
| | Read more>>
| |
| October 09, 2006 | Alligator Bioscience to address immunogenicity with Epibase®
| | Raed more>>
| |
| September 23, 2005 | Alligator Bioscience AB enters into drug development collaboration with major European pharmaceutical company.
| | Read more>>
| |
| June 10, 2004 | | Alligator Bioscience concludes successful project for AstraZeneca
| | Read more>>
| |
| February 11, 2003 | | Alligator Bioscience and AB Enzymes enter into enzyme development collaboration
| | Read more>>
| |
| October 7, 2002 | | Alligator Bioscience and AstraZeneca enter into technology collaboration agreement regarding drug development
| | Read more>>
| |
|
|
|
|
|
|
|
|
|